Is BLTE or BNTX more profitable?

Belite Bio has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% BioNTech -44.39% -5.30% -4.62%

Does the media favor BLTE or BNTX?

In the previous week, BioNTech had 3 more articles in the media than Belite Bio. MarketBeat recorded 6 mentions for BioNTech and 3 mentions for Belite Bio. BioNTech's average media sentiment score of 1.38 beat Belite Bio's score of 0.47 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is INSM or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Belite Bio's return on equity of -13.14% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Belite Bio N/A -13.14% -12.88%

Does the media prefer INSM or BLTE?

In the previous week, Insmed had 22 more articles in the media than Belite Bio. MarketBeat recorded 25 mentions for Insmed and 3 mentions for Belite Bio. Insmed's average media sentiment score of 1.22 beat Belite Bio's score of 0.47 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 18 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ROIV or BLTE?

In the previous week, Roivant Sciences had 9 more articles in the media than Belite Bio. MarketBeat recorded 12 mentions for Roivant Sciences and 3 mentions for Belite Bio. Roivant Sciences' average media sentiment score of 1.59 beat Belite Bio's score of 0.47 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VTRS or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Belite Bio N/A -13.14% -12.88%

Does the media refer more to VTRS or BLTE?

In the previous week, Viatris and Viatris both had 3 articles in the media. Viatris' average media sentiment score of 1.87 beat Belite Bio's score of 0.47 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BLTE or MRNA more profitable?

Belite Bio has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Belite Bio's return on equity of -13.14% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Moderna -143.55% -26.64% -19.32%

Does the media refer more to BLTE or MRNA?

In the previous week, Moderna had 16 more articles in the media than Belite Bio. MarketBeat recorded 19 mentions for Moderna and 3 mentions for Belite Bio. Moderna's average media sentiment score of 0.57 beat Belite Bio's score of 0.47 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Belite Bio (BLTE) Competitors

$138.16 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$138.10 -0.06 (-0.04%)

As of 06/12/2026 05:34 PM Eastern

Compare

BLTE vs. BNTX, INSM, ROIV, VTRS, and MRNA

Should you buy Belite Bio stock or one of its competitors? MarketBeat compares Belite Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Belite Bio include BioNTech (BNTX), Insmed (INSM), Roivant Sciences (ROIV), Viatris (VTRS), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does Belite Bio compare to BioNTech?

Belite Bio (NASDAQ:BLTE) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, BioNTech had 3 more articles in the media than Belite Bio. MarketBeat recorded 6 mentions for BioNTech and 3 mentions for Belite Bio. BioNTech's average media sentiment score of 1.38 beat Belite Bio's score of 0.47 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Belite Bio presently has a consensus target price of $203.00, suggesting a potential upside of 46.93%. BioNTech has a consensus target price of $129.56, suggesting a potential upside of 43.10%. Given Belite Bio's higher probable upside, equities research analysts plainly believe Belite Bio is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Belite Bio has higher earnings, but lower revenue than BioNTech. Belite Bio is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
BioNTech	$3.25B	7.05	-$1.29B	-$5.88	N/A

Belite Bio has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
BioNTech	-44.39%	-5.30%	-4.62%

Belite Bio has a beta of -1.24, suggesting that its stock price is 224% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market.

Summary

BioNTech beats Belite Bio on 12 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Insmed?

Insmed (NASDAQ:INSM) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

0.5% of Belite Bio shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Insmed had 22 more articles in the media than Belite Bio. MarketBeat recorded 25 mentions for Insmed and 3 mentions for Belite Bio. Insmed's average media sentiment score of 1.22 beat Belite Bio's score of 0.47 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	18 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, indicating that its stock price is 224% less volatile than the broader market.

Insmed currently has a consensus price target of $212.50, indicating a potential upside of 117.17%. Belite Bio has a consensus price target of $203.00, indicating a potential upside of 46.93%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts clearly believe Insmed is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Belite Bio has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Belite Bio's return on equity of -13.14% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Belite Bio	N/A	-13.14%	-12.88%

Belite Bio has lower revenue, but higher earnings than Insmed. Belite Bio is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	34.97	-$1.28B	-$5.75	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Summary

Insmed beats Belite Bio on 9 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Roivant Sciences had 9 more articles in the media than Belite Bio. MarketBeat recorded 12 mentions for Roivant Sciences and 3 mentions for Belite Bio. Roivant Sciences' average media sentiment score of 1.59 beat Belite Bio's score of 0.47 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, indicating that its stock price is 224% less volatile than the broader market.

Belite Bio has lower revenue, but higher earnings than Roivant Sciences. Belite Bio is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,615.84	-$299.77M	-$0.60	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Belite Bio has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Belite Bio's return on equity of -13.14% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Belite Bio	N/A	-13.14%	-12.88%

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Roivant Sciences presently has a consensus target price of $33.59, indicating a potential upside of 11.82%. Belite Bio has a consensus target price of $203.00, indicating a potential upside of 46.93%. Given Belite Bio's higher possible upside, analysts clearly believe Belite Bio is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Roivant Sciences beats Belite Bio on 9 of the 15 factors compared between the two stocks.

How does Belite Bio compare to Viatris?

Viatris (NASDAQ:VTRS) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Belite Bio	N/A	-13.14%	-12.88%

Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, meaning that its stock price is 224% less volatile than the broader market.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Viatris and Viatris both had 3 articles in the media. Viatris' average media sentiment score of 1.87 beat Belite Bio's score of 0.47 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 6.19%. Belite Bio has a consensus target price of $203.00, suggesting a potential upside of 46.93%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts clearly believe Belite Bio is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Belite Bio has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.34	-$3.51B	-$0.26	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Summary

Viatris and Belite Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Belite Bio compare to Moderna?

Belite Bio (NASDAQ:BLTE) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Belite Bio has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Belite Bio's return on equity of -13.14% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Moderna	-143.55%	-26.64%	-19.32%

Belite Bio has higher earnings, but lower revenue than Moderna. Belite Bio is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Moderna	$1.94B	10.19	-$2.82B	-$8.15	N/A

Belite Bio has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Belite Bio presently has a consensus price target of $203.00, indicating a potential upside of 46.93%. Moderna has a consensus price target of $36.60, indicating a potential downside of 26.67%. Given Belite Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Belite Bio is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Moderna had 16 more articles in the media than Belite Bio. MarketBeat recorded 19 mentions for Moderna and 3 mentions for Belite Bio. Moderna's average media sentiment score of 0.57 beat Belite Bio's score of 0.47 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Belite Bio beats Moderna on 9 of the 15 factors compared between the two stocks.

Get Belite Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLTE vs. The Competition

Export

Metric	Belite Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.54B	$3.39B	$6.53B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-54.61	20.00	24.22	24.42
Price / Sales	N/A	305.69	511.60	109.90
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	6.73	8.32	10.65	6.82
Net Income	-$77.61M	$23.94M	$3.57B	$337.56M
7 Day Performance	-1.05%	1.84%	0.58%	1.17%
1 Month Performance	-3.38%	-0.04%	1.54%	3.16%
1 Year Performance	132.01%	44.82%	25.40%	30.58%

Belite Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLTE Belite Bio	2.7366 of 5 stars	$138.16 flat	$203.00 +46.9%	+132.0%	$5.54B	N/A	N/A	10
BNTX BioNTech	4.5676 of 5 stars	$85.31 -0.2%	$129.56 +51.9%	-15.0%	$21.59B	$3.25B	N/A	7,807	Positive News
INSM Insmed	3.4231 of 5 stars	$96.94 +2.9%	$212.50 +119.2%	-0.9%	$21.02B	$819.56M	N/A	1,664	Analyst Forecast Options Volume
ROIV Roivant Sciences	2.2976 of 5 stars	$28.40 -0.3%	$33.59 +18.3%	+165.4%	$20.46B	$8.26M	N/A	860	Positive News
VTRS Viatris	3.2284 of 5 stars	$16.02 +0.6%	$17.50 +9.2%	+84.8%	$18.69B	$14.30B	N/A	30,000	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLTE) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Belite Bio (BLTE) Competitors